Worldwide there are more than 600 Neurological Disorders affecting millions of people that result in a vast number of injuries, death, and disability every year. These disorders have a high incidence and prevalence and the lack of awareness, limited diagnostics, and treatment approaches create an extra burden. These disorders are also associated with stigmatization and discrimination. Neurological Disorders encompass a large number of diseases however, Stroke, Seizures (Epilepsy), Dementia (Alzheimer’s Disease), Parkinson’s Disease, Multiple Sclerosis, Migraine are the most common.
To address the rising burden, some of the key companies in the Neurological Disorders market such as Cefaly, Neurolief Ltd., Chordate Medical, Theranica Bio-Electronics Ltd., Electrocore Inc., eNeura Inc., BMedical Pty Ltd, Prolivio, Cirrus Healthcare Products, Cirrus Healthcare Products, Biogen, Novartis, Merck, Imcyse, NervGen, Cortexyme, Cerevel Therapeutics, Amneal Pharmaceuticals, Pharma Two B, Cerevance, AbbVie, Theranexus, Eisai, BioArctic AB, Hoffmann-La Roche/Chugai Pharmaceuticals, Anavex Life Sciences, Neurimmune, Aquestive Therapeutics, UCB Biopharma, Marinus Pharmaceuticals, Takeda, Jazz Pharmaceuticals, Zynerba, Athersys, Abbvie, Bristol-Myers Squibb, Lumosa Therapeutics, Teijin Pharma Limited, and several others are diligently involved in developing innovative therapies. The launch of the emerging therapies is expected to significantly improve the health outcome of the people affected with Neurological Disorders.
For more details, visit: Companies in Neurological Disorders Therapy Market